Shares of Bolt Biotherapeutics (NASDAQ: BOLT) crashed 55.8% on Monday. The steep decline came after the company presented interim data from a phase 1/2 study evaluating BDC-1001 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress that's being held virtually this week. Investors were clearly disappointed with Bolt's interim results.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting